ARCHIVES

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

National Action Plan Issues RFA For Grant Supplements

April 21, 1995

NCI Getting a Lot For a Little Money It Spends Overseas, International Program Director Says

June 17, 1977

NCI Gets Concept Approval for New Communications Network

May 27, 1988

In Brief: Christopher Walsh Named Dana-Farber President; Sachs Leaves NCI; Acoustic Neuroma Conference

August 16, 1991

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

FCRC Decision Due In 90 Days, Upton Says

November 24, 1978